At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
PROTHERACYTES +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EXpanded CELL ENdocardiac Transplantation (EXCELLENT)
In Brief
A Phase 2 clinical trial evaluating PROTHERACYTES and Standard Treatment for CHF post AMI for Acute Myocardial Infarction. Completed, enrolled 49 participants across 13 sites in 2 countries.
Detailed Summary
A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process, and injected in patients with an acute myocardial infarction and a LVEF remaining below 50% versus standard of care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction
CountriesFrance, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartFeb 2016
Primary CompletionMar 2024
TodayJul 2026
First PostedFeb 1, 2016
Enrollment StartFeb 10, 2016
Primary CompletionMar 15, 2024
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 10.4 years ago
Interventions
PROTHERACYTESdrug
ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
Standard Treatment for CHF post AMIdrug